Dynamics of IL-4 and IL-13 expression in the airways of sheep following allergen challenge

BMC Pulmonary Medicine

Volumn 15, Issue 1, 2015, Pages

  Liravi, Bahar ^a   Piedrafita, David ^b   Nguyen, Gary ^a   Bischof, Robert J ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

^c HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HOUSE DUST ALLERGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ALLERGEN;

ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNOHISTOLOGY; LUNG ALVEOLUS MACROPHAGE; LUNG LAVAGE; LYMPHOCYTE; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; SHEEP; ANIMAL; ASTHMA; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHUS HYPERREACTIVITY; CYTOLOGY; DISEASE MODEL; IMMUNOLOGY; PATHOPHYSIOLOGY; PYROGLYPHIDAE; TH1 TH2 BALANCE;

ALLERGENS; ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; FEMALE; INTERLEUKIN-13; INTERLEUKIN-4; PYROGLYPHIDAE; SHEEP; TH1-TH2 BALANCE;

EID: 84941266690     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-015-0097-9     Document Type: Article

References (67)

1. Hall S, Agrawal DK. Key mediators in the immunopathogenesis of allergic asthma. Int Immunopharmacol. 2014;23(1):316-29.
2. Murdoch JR, Lloyd CM. Chronic inflammation and asthma. Mutat Res. 2010;690(1-2):24-39.
3. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-92.
4. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38(6):872-97.
5. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol. 2010;22(5):347-52.
6. Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci. 2012;8(9):1281-90.
7. Finkelman FD, Boyce JA, Vercelli D & Rothenberg ME. Key advances in mechanisms of asthma, allergy, and immunology in 2009. J Allergy Clin Immunol. 2010;125(2):312-8.
8. Daher S,Santos LM,Sole D,De Lima MG,Naspitz CK &Musatti CC. Interleukin-4 and soluble CD23 serum levels in asthmatic atopic children. J Investig Allergol Clin Immunol. 1995;5(5):251-4.
9. Walker C,Kaegi MK,Braun P &Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol. 1991;88(6):935-42.
10. Shi H,Qin S,Huang G,Chen Y,Xiao C,Xu, H et al. Infiltration of eosinophils into the asthmatic airways caused by interleukin 5. Am J Respir Cell Mol Biol. 1997;16(3):220-4.
11. Herrick CA, Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat Rev Immunol. 2003;3(5):405-12.
12. Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol Rev. 2004;202:175-90.
13. Humbert M,Durham SR,Kimmitt P,Powell N,Assoufi B,Pfister Ret al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol. 1997;99(5):657-65.
14. Kroegel C,Julius P,Matthys H,Virchow JcJ,Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J. 1996;9(5):899-904.
15. Prieto J,Lensmar C,Roquet A,van der Ploeg I,Gigliotti D,Eklund A &Grunewald J. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med. 2000;94(8):806-14.
16. Grunig G,Warnock M,Wakil AE,Venkayya R,Brombacher F,Rennick DM et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282(5397):2261-3.
17. Wills-Karp M,Luyimbazi J,Xu X,Schofield B,Neben TY,Karp CL &Donaldson DD. Interleukin-13: central mediator of allergic asthma. Science. 1998;282(5397):2258-61.
18. Blanchard C,Mishra A,Saito-Akei H,Monk P,Anderson I &Rothenberg ME. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005;35(8):1096-103.
19. De Boever EH,Ashman C,Cahn AP,Locantore NW,Overend P,Pouliquen IJ et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133(4):989-96.
20. Piper E,Brightling C,Niven R,Oh C,Faggioni R,Poon K et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41(2):330-8.
21. Collie DD. Comparative, complementary and relevant: the immunological basis of ovine lung allergic responses. Clin Exp Allergy. 2003;33(3):282-6.
22. Meeusen EN,Snibson KJ,Hirst SJ,Bischof RJ. Sheep as a model species for the study and treatment of human asthma and other respiratory diseases. Drug Discov Today Dis Models. 2010;6(4):101-6.
23. Bischof RJ,Snibson K,Shaw R,Meeusen EN. Induction of allergic inflammation in the lungs of sensitized sheep after local challenge with house dust mite. Clin Exp Allergy. 2003;33(3):367-75.
24. Snibson KJ,Bischof RJ,Slocombe RF,Meeusen EN. Airway remodelling and inflammation in sheep lungs after chronic airway challenge with house dust mite. Clin Exp Allergy. 2005;35(2):146-52.
25. Kirschvink N, Reinhold P. Use of alternative animals as asthma models. Curr Drug Targets. 2008;9(6):470-84.
26. Allen JE,Bischof RJ,Sucie Chang HY,Hirota JA,Hirst SJ,Inman MD et al. Animal models of airway inflammation and airway smooth muscle remodelling in asthma. Pulm Pharmacol Ther. 2009;22(5):455-65.
27. Miller LA,Hurst SD,Coffman RL,Tyler NK,Stovall MY,Chou DL et al. Airway generation-specific differences in the spatial distribution of immune cells and cytokines in allergen-challenged rhesus monkeys. Clin Exp Allergy. 2005;35(7):894-906.
28. Bischof RJ,Snibson KJ,Van Der Velden J,Meeusen EN. Immune response to allergens in sheep sensitized to house dust mite. J Inflamm (Lond). 2008;5:16.
29. Hope JC,Kwong LS,Entrican G,Wattegedera S,Vordermeier HM,Sopp P &Howard CJ. Development of detection methods for ruminant interleukin (IL)-12. J Immunol Methods. 2002;266(1-2):117-26.
30. Kwong LS,Hope JC,Thom ML,Sopp P,Duggan S,Bembridge GP &Howard CJ. Development of an ELISA for bovine IL-10. Vet Immunol Immunopathol. 2002;85(3-4):213-23.
31. Abeynaike L, Meeusen ENT, Bischof RJ. An ovine tracheal explant culture model for allergic airway inflammation. J Inflamm (Lond). 2010;7:46-55.
32. Bischof RJ, Meeusen EN. Cellular kinetics of an allergic-type response in a sheep mammary gland model of inflammation. Clin Exp Allergy. 2002;32(4):619-26.
33. Gallelli L,Busceti MT,Vatrella A,Maselli R &Pelaia G. Update on anticytokine treatment for asthma. Biomed Res Int. 2013;2013:104315.
34. Fahy JV. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015;15(1):57-65.
35. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015;135(2):299-310. quiz 311.
36. Walsh G.M. Anti-IL-4/-13 based therapy in asthma. Expert Opin Emerg Drugs. 2015;20(3):349-52.
37. Ingram JL, Kraft M. IL-13 in asthma and allergic disease: asthma phenotypes and targeted therapies. J Allergy Clin Immunol. 2012;130(4):829-42. quiz 843-4.
38. Abbas AR,Jackman JK,Bullens SL,Davis SM,Choy DF,Fedorowicz G et al. Lung gene expression in a rhesus allergic asthma model correlates with physiologic parameters of disease and exhibits common and distinct pathways with human asthma and a mouse asthma model. Am J Pathol. 2011;179(4):1667-80.
39. Coffman RL, Hessel EM. Nonhuman primate models of asthma. J Exp Med. 2005;201(12):1875-9.
40. Dewachi O,Joubert P,Hamid Q &Lavoie JP. Expression of interleukin (IL)-5 and IL-9 receptors on neutrophils of horses with heaves. Vet Immunol Immunopathol. 2006;109(1-2):31-6.
41. Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res. 2001;2(2):66-70.
42. Collie DD,McLean N,Sallenave JM,Baker A,Blundell R,Milne E et al. Local lung responses following endobronchial elastase and lipopolysaccharide instillation in sheep. Int J Chron Obstruct Pulmon Dis. 2006;1(2):189-99.
43. Collie DD,Baker A,Mauchline S,Porteous D &Mc Lachlan G. Ovine bronchoalveolar lavage cellularity: reproducibility and the effect of multiple repeated lavage. Res Vet Sci. 1999;67(2):137-40.
44. Temann UA,Geba GP,Rankin JA &Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med. 1998;188(7):1307-20.
45. Moreira AP, Hogaboam CM. Macrophages in allergic asthma: fine-tuning their pro- and anti-inflammatory actions for disease resolution. J Interferon Cytokine Res. 2011;31(6):485-91.
46. Loke P,Nair MG,Parkinson J,Guiliano D,Blaxter M &Allen JE. IL-4 dependent alternatively-activated macrophages have a distinctive in vivo gene expression phenotype. BMC Immunol. 2002;3:7.
47. Muller U,Stenzel W,Kohler G,Werner C,Polte T,Hansen G et al. IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans. J Immunol. 2007;179(8):5367-77.
48. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11(10):889-96.
49. Van Dyken SJ, Locksley RM. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Annu Rev Immunol. 2013;31:317-43.
50. Melgert BN,ten Hacken NH,Rutgers B,Timens W,Postma DS & Hylkema MN. More alternative activation of macrophages in lungs of asthmatic patients. J Allergy Clin Immunol. 2011;127(3):831-3.
51. Yang M,Kumar RK,Hansbro PM &Foster PS. Emerging roles of pulmonary macrophages in driving the development of severe asthma. J Leukoc Biol. 2012;91(4):557-69.
52. Kang CM,Jang AS,Ahn MH,Shin JA,Kim JH,Choi YS et al. Interleukin-25 and interleukin-13 production by alveolar macrophages in response to particles. Am J Respir Cell Mol Biol. 2005;33(3):290-6.
53. La Flamme AC,Kharkrang M,Stone S,Mirmoeini S,Chuluundorj D &Kyle R. Type II-activated murine macrophages produce IL-4. PLoS One. 2012;7(10), e46989.
54. Balhara J, Gounni AS. The alveolar macrophages in asthma: a double-edged sword. Mucosal Immunol. 2012;5(6):605-9.
55. Hancock A,Armstrong L,Gama R &Millar A. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol. 1998;18(1):60-5.
56. Varin A,Mukhopadhyay S,Herbein G &Gordon S. Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion. Blood. 2010;115(2):353-62.
57. Ullah MA,Revez JA,Loh Z,Simpson J,Zhang V,Bain L et al. Allergen-induced IL-6 trans-signaling activates gammadelta T cells to promote type 2 and type 17 airway inflammation. J Allergy Clin Immunol. 2015.doi: 10.1016/j.jaci.2015.02.032 .
58. Colavita AM,Hastie AT,Musani AI,Pascual RM,Reinach AJ,Lustine HT et al. Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects. J Allergy Clin Immunol. 2000;106(5):880-6.
59. Thorburn AN, Hansbro PM. Harnessing regulatory T cells to suppress asthma: from potential to therapy. Am J Respir Cell Mol Biol. 2010;43(5):511-9.
60. McAleer JP, Kolls JK. Directing traffic: IL-17 and IL-22 coordinate pulmonary immune defense. Immunol Rev. 2014;260(1):129-44.
61. Yang Z,Grinchuk V,Urban JF Jr,Bohl J,Sun R,Notari L et al. Macrophages as IL-25/IL-33-responsive cells play an important role in the induction of type 2 immunity. PLoS One. 2013;8(3), e59441.
62. Willis CR,Siegel L,Leith A,Mohn D,Escobar S,Wannberg S et al. IL-17RA signaling drives airway inflammation and bronchial hyper reactivity in allergic asthma. Am J Respir Cell Mol Biol. 2015.doi: 10.1165/rcmb.2015-0038OC .
63. Hallstrand TS,Hackett TL,Altemeier WA,Matute-Bello G,Hansbro PM &Knight DA. Airway epithelial regulation of pulmonary immune homeostasis and inflammation. Clin Immunol. 2014;151(1):1-15.
64. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol. 2009;182(8):4994-5002.
65. Collison A,Herbert C,Siegle JS,Mattes J,Foster PS &Kumar RK. Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment. J Allergy Clin Immunol. 2011;128(1):160-7. e4.
66. Rodriguez A,Vigorito E,Clare S,Warren MV,Couttet P,Soond DR et al. Requirement of bic/microRNA-155 for normal immune function. Science. 2007;316(5824):608-11.
67. Malmhall C,Alawieh S,Lu Y,Sjostrand M,Bossios A,Eldh M &Radinger M. MicroRNA-155 is essential for T(H)2-mediated allergen-induced eosinophilic inflammation in the lung. J Allergy Clin Immunol. 2014;133(5):1429-38. 1438 e1-7.